Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 23;9:e2200331. doi: 10.1200/GO.22.00331

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3 — Anti–SARS-CoV-2 RBD IgG levels before and after COVID-19 vaccination (ChAdOx1 and CoronaVac vaccine). In the ChAdOx1 vaccination group (left), there was no difference in the anti–SARS-CoV-2 S RBD IgG levels at 4 weeks after completing vaccination between chemotherapy and nonchemotherapy groups, 818 and 1,061 U/mL, respectively (P = .075). Patients receiving the CoronaVac vaccination (right) showed a statistically significant difference in anti–SARS-CoV-2 RBD IgG levels between the two groups, 7 U/mL in the CMT group and 90 U/mL in the non-CMT group (P < .001). CMT, chemotherapy; IgG, immunoglobulin G; IQR, interquartile range; NA, not available; non-CMT, nonchemotherapy; RBD, receptor-binding domain.